

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR 7918 10/650,591 08/27/2003 Noubar B. Afeyan COTH-P02-001 **EXAMINER** 28120 08/09/2005 7590 FISH & NEAVE IP GROUP MEAH, MOHAMMAD Y **ROPES & GRAY LLP ART UNIT** PAPER NUMBER ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624 1652

DATE MAILED: 08/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)	•	
Office Action Summary		10/650,591	AFEYAN ET AL.	AFEYAN ET AL.	
		Examiner	Art Unit		
		Mohammad Meah	1652		
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover sheet with	the correspondence ad	dress	
THE I - External after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION, asions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. a period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statuted patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a repoly within the statutory minimum of thirty will apply and will expire SIX (6) MONTICE, cause the application to become ABA	oly be timely filed (30) days will be considered timely HS from the mailing date of this condition (35 U.S.C. § 133).		
Status					
1) Responsive to communication(s) filed on 02 July 2005.					
2a) <u></u>	This action is FINAL . 2b)⊠ Thi	This action is non-final.			
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Dispositi	ion of Claims				
5) 6) 7)	6) Claim(s) is/are rejected.				
Applicati	ion Papers				
9) The specification is objected to by the Examiner.					
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.				
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.				
Priority ι	under 35 U.S.C. § 119		•	•	
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s)					
· —	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948)	<i>,</i> —	ımmary (PTO-413) /Mail Date	• •	
3) Infor	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 er No(s)/Mail Date	5) D Nation of 1 of	formal Patent Application (PTC	D-152)	

Application/Control Number: 10/650,591

Art Unit: 1652

DETAILED ACTION

Claims 1-41 in this application are pending.

Election/Restrictions

Inventions in claims 1-41 comprise adzymes (a fusion protein comprising protease domains and targeting domains {comprising antibody and / or polypeptide} attached via no linker or linker). Wherein the protease is selected from any protease (claims 1, 41) or zymogen (claim 3) or serine proteinase and metalloproteinase (claim 4). Protease includes a wide variety of different protease enzymes as listed in pages 85-90 of specification. Serine proteinase and metalloproteinase also include a wide variety of different enzymes as stated in page 35-36. Targeting moiety is selected from any class of a wide variety of species of polypeptide, polypeptide complex, antibody, Fab, scFv, artificial protein, etc. Each catalytic domain of the fusion proteins encompassed by the instant claims is a patentably distinct protein having a different structure than the other catalytic domains encompassed by the instant claims. Similarly, each specific targeting domain fusion encompassed by the instant claims is a patentably distinct protein having a different structure than the other targeting domains encompassed by the instant claims. Each specific linker encompassed by the instant claims is a patentably distinct amino acid sequence having a different structure than the other linkers encompassed by the instant claims. N combinations of catalytic domain with N combinations of targeting domain will produce N^2 (such as 10 X10 = 100) patentably distinct adzymes having different structures. Furthermore each specific fusion protein will have distinct functional properties as well. As such each adzyme

Application/Control Number: 10/650,591

Art Unit: 1652

fusion protein is an independent invention. In view of the enormous number of independent inventions encompassed the examiner has not attempted to exhaustively list each independent invention herein. Applicants are required to identify a specific adzyme fusion protein for examination by electing a specific protease or proteinase and a specific targeting domain. Applicants are further required to identify which claims encompass the elected invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 1652

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD

Examiner, Art Unit 1652

Recombinant Enzymes, 3C31 Remsen Bld 400 Dulany Street, Alexandria, VA 22314

Telephone: 517-272-1261

PRIMARY EXAMINER SAOUP 1800